John Trizzino compensation by year
NOVAVAX Summary Compensation Table · all 10 fiscal years held| Component | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Salary | $359,500 | $366,102 | $378,078 | $390,701 | $415,892 | $456,250 | $506,250 | $526,250 | $582,825 | $310,016 |
| Bonus | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $0 | $0 | $0 | $330,831 | $831,410 | $427,329 | $1,075,170 | $604,090 | $776,160 | $368,624 |
| Option awards | $790,315 | $425,000 | $890,700 | $584,103 | $19,819,717 | $0 | $1,361,844 | $603,243 | $0 | $209,724 |
| Non-equity incentive | $0 | $149,145 | $53,498 | $150,421 | $249,535 | $169,383 | $122,766 | $131,100 | $261,911 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $7,387 | $7,500 | $7,500 | $9,546 | $11,400 | $11,217 | $12,200 | $13,200 | $12,521 | $821,586 |
| Total | $1,157,202 | $947,747 | $1,329,776 | $1,465,602 | $21,327,954 | $1,064,179 | $3,078,230 | $1,877,883 | $1,633,417 | $1,709,950 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: NOVAVAX INC DEF 14A filed April 27, 2026, accession 0001628280-26-027328, and prior-year filings. Open the filing on EDGAR.
How this page was built: the NOVAVAX INC filed document, accession 0001628280-26-027328. Every figure is read from that document and cited to the page and table it appears in. Filed April 27, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 96,000 | $645,120 | — |
| RSU | 28,890 | $194,141 | — |
| Option | 46,777 | — | $9.01 |
| Option | 1,297 | — | $77.77 |
Per the Outstanding Equity Awards at Fiscal Year-End table in NOVAVAX INC's FY2025 proxy; value at the fiscal year-end close, as the company printed it.
NOVAVAX’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| John Jacobs | President and CEO | $8,856,015 |
| Elaine O'Hara | EVP, Chief Strategy Officer | $3,688,276 |
| James Kelly | EVP, Chief Financial Officer and Treasurer | $2,986,228 |
| Mark Casey | EVP, Chief Legal Officer and Corporate Secretary | $2,810,453 |
| Ruxandra Draghia-Akli | Former EVP, Head of Research & Development | $2,303,380 |
| John Trizzino · this page | Former President and Chief Operating Officer | $1,709,950 |
John Trizzino's compensation dossier, NOVAVAX
You have read John Trizzino's totals and holdings. The dossier adds each equity grant NOVAVAX disclosed for John Trizzino and NOVAVAX's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full NOVAVAX compensation record
free company briefThis page is one person within NOVAVAX's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the NOVAVAX proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order NOVAVAX's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are NOVAVAX's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order NVAX
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.